Several studies have been published correlating several biochemical markers to stroke, but none are approved for clinical use. Ischemia-modified albumin (IMA) is the only marker which has been approved by Food and Drug Administration (FDA) of the United States for early diagnosis of myocardial ischemia. IMA is a novel marker developed by quantifying the decrease in metal binding capacity. Several attempts have been made to understand the significance of IMA in context with acute ischemic condition other than myocardial infarctions such as acute stroke, and pulmonary embolism, but the data show variable results, and the available data are insufficient and inconclusive. [3, 4] Diabetes mellitus (DM) is frequently associated with stroke. Diabetes is known to accelerate the atherosclerosis process and hence increases the risk of stroke. DM is also known to influence the IMA concentration. [5] There are many factors which can affect the IMA levels in stroke patients. Few studies suggest that the serum albumin levels could influence the IMA estimation and hence suggested few modifications to the IMA estimation. [6] There are many studies in the literature which have reported decreased albumin levels in acute stroke patients. Hence, this study was undertaken to assess the correlation of serum albumin levels with the IMA levels in acute stroke patients with or without DM.
Subjects and Methods

Study population
This study comprised the patients of acute stroke (diagnosed clinically and radiologically) with and without DM, attending casualty and intensive care unit of KLES' Dr. Prabhakar Kore Hospital and Medical Research Centre, Belagavi. Apparently, healthy volunteers who attended the blood bank of Dr. Prabhakar Kore Hospital and Medical Research Centre were taken as controls. This study included ninety subjects of either sex, aged more than 18 years, of which thirty cases of acute stroke with diabetes, thirty cases of acute stroke without diabetes and thirty normal healthy controls. Informed and written consent was obtained from all the subjects involved in the study. Institutional ethical committee clearance was obtained before start of the study.
Patients presenting with the symptoms of acute stroke within 12 h of onset of symptoms were included in the study. Clinical data with other relevant information were obtained as per the proforma. Initially, blood sample was drawn from all the patients immediately after the clinical diagnosis. Patients with confirmed diagnosis of acute stroke by brain computerized tomography and/or magnetic resonance imaging were included in the case group. Detailed history including diabetes history was taken and included them in different groups accordingly. The patients with diabetes history who are on treatment for hyperglycemia (either oral hypoglycemic drugs or insulin) were only included in diabetes group. Serum was separated from the blood and used for further analyses.
Analytical methods
IMA was measured by albumin cobalt binding test as described by Bar-Or et al. [7] To 200 µl of serum 50 µl of cobalt chloride was added and kept for 10 min incubation. Dithiothreitol 50 µl was added and incubated for 2 min. Later, 1 ml of sodium chloride was added. The absorbance of assay mixture was read at 470 nm using a spectrophotometer and values recorded in absorbance units.
Serum albumin was measured by SIEMENS Dimension ®
RxL Max clinical chemistry system based on the bromocresol purple (BCP) dye-binding method. In this assay, serum albumin quantitatively binds to BCP to form an albumin-BCP complex that is measured as an endpoint reaction at 596/694 nm.
Statistical analysis
SPSS software version 20 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp.) was used for the statistical analyses. The measured parameters were expressed as mean ± standard deviation. The data generated were compared using ANOVA at 5% level of significance. Correlations between the parameters were done using Pearson's correlation coefficient test at 5% level of significance.
Results
There was a statistically significant difference between the three groups with respect to mean serum albumin values when compared with ANOVA (P < 0.01). Mean serum albumin value of "control" group (4.0 ± 0.4 g/dL) was higher than the "stroke with DM" (3.6 ± 0.6 g/dL) or "stroke without DM" (3.8 ± 0.4 g/dL) groups. Comparison of serum albumin values of three groups with each other by post hoc Bonferroni test showed significant difference (P < 0.01) between "control" and "stroke with DM" groups [ Table 1 and Graph 1].
Mean IMA values were high in "stroke with DM" (0.23 ± 0.03) or "stroke without DM" (0.21 ± 0.03) groups when compared with the "controls" (0.16 ± 0.03). Indian Journal of Health Sciences and Biomedical Research KLEU  Jan-Apr 2017  Vol 10  Issue 1
There was a statistically significant difference (P < 0.001) between the three groups when compared by ANOVA [ Table 2 ].
There was no statistically significant correlation between IMA and serum albumin levels in all the three groups. In "stroke with DM" group, there was a statistically insignificant negative correlation between IMA values and serum albumin values (r = −0.103, P = 0.58). In "stroke without DM" group, there was a statistically insignificant positive correlation between IMA values and serum albumin values (r = 0.111, P = 0.56). In "control" group, there was a statistically insignificant negative correlation (r = −0.007, P = 0.96) between IMA values and serum albumin values [Graphs 2-4].
Discussion
IMA, the only FDA approved biomarker for ischemia has been shown to increase in various ischemic conditions including coronary artery disease, acute stroke, and mesenteric ischemia. Originally, IMA was studied in acute coronary syndrome patients.
In this study, IMA level was significantly higher in stroke patients than controls. This is in accordance with many previous studies. [8, 9] The exact mechanism of formation of IMA in any ischemia including stroke is not known. The proposed mechanisms for conversion of serum albumin to IMA include hypoxia, acidosis, superoxide radical injury, exposure to free iron and copper, etc. Reactive oxygen species are well-known as factors responsible for chemical and molecular damage of many biological molecules. Most of the recent studies reported that IMA levels increased in in "stroke with diabetes mellitus," "stroke without diabetes mellitus," and "control" groups Graph 2: Correlation of ischemia modified albumin with serum albumin in "stroke with diabetes mellitus" group. r (Correlation coefficient) = −0.103, P = 0.58
Graph 3:
Correlation of ischemia-modified albumin with serum albumin in "stroke without diabetes mellitus" group. r (Correlation coefficient) =0.111, P = 0.56 many diseases where oxidative stress is proposed as the main mechanism supporting the hypothesis that IMA generation depends strongly on the high oxidative stress state.
In our study, we also estimated and compared serum albumin levels in all the three study groups. We also tried to assess the correlation of serum albumin with IMA levels in the three groups separately. Serum albumin values were higher in "control" group than "stroke with DM" or "stroke without DM" groups. This is in line with results of many studies which analyzed the role of albumin in acute stroke. The First National Health and Nutrition Examination Survey I epidemiologic follow-up study showed lower serum albumin level is associated with higher stroke incidence and death risk due to stroke. [10] Xu et al. also observed in their Northern Manhattan study, lower albumin levels in stroke patients with various etiologies. [11] Folsom et al. reported lower serum albumin levels in diabetics than nondiabetics which was also observed in our study. [12] Gaze et al. studied the correlation between serum albumin and IMA in healthy nonischemic patients and observed that there was a significant (r = −0.888, P < 0.0001) negative correlation between IMA and albumin both over the entire range of albumin concentrations and in the low albumin concentration subgroup (r = −0.85, P < 0.0001), but there was a less significant negative correlation between the two in the group with albumin levels within the reference interval. [13] A study done by Kumar et al. revealed a significant negative correlation (r = −0.473, P < 0.001) between serum albumin levels and IMA levels in acute myocardial infarction patients. [6] No study has reported the correlation of IMA with serum albumin in acute stroke patients.
Conclusion
In our study, there was a negative correlation in "stroke with DM" or "control" groups; although, it was statistically not significant. In "stroke without DM" group, there was a statistically insignificant positive correlation. Hence, it can be concluded that IMA concentration is independent of serum albumin concentration in acute stroke patients and probably the IMA concentration depends on the severity and duration of ischemia or oxidative stress.
Some of the limitations of the present study include small sample size for the results to be generalized for acute stroke diagnosis. The effect of DM on the IMA levels and serum albumin levels was not considered in the present study. Further large-scale studies devoid of the above limitations are required to confirm the findings of this study.
Graph 4:
Correlation of ischemia-modified albumin with serum albumin in "control" group. r (Correlation coefficient) = −0.007, P = 0.96
